Clinical trial
Assessment of the Effects of Zegerid Powder for Oral Suspension 40 mg on 24-Hour and Nocturnal Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease and Barrett's Esophagus
NCT01129778 is registered in ClinicalTrials.gov with Stanford University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Assessment of the Effects of Zegerid Powder for Oral Suspension 40 mg on 24-Hour and Nocturnal Esophageal Acid Exposure in Patients With Gastroesophageal Reflux Disease and Barrett's Esophagus
- Lead sponsor
- Stanford University
- Phase
- Not applicable
- Overall status
- Terminated
- Start date
- November 30, 2009
- Completion date
- December 31, 2010
- Enrollment
- 27 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.